Clinical Trials Using Androgen Receptor Antisense Oligonucleotide AZD5312

Clinical trials are research studies that involve people. The clinical trials on this list are studying Androgen Receptor Antisense Oligonucleotide AZD5312. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trial 1 of 1
  • IONIS-AR-2.5Rx and Enzalutamide in Treating Patients with Metastatic Castration-Resistant Prostate Cancer

    This phase Ib / II trial studies the side effects and best dose of IONIS-AR-2.5Rx when given together with enzalutamide and to see how well they work in treating patients with castration-resistant prostate cancer that has spread to other places in the body. Drugs used in chemotherapy, such as IONIS-AR-2.5Rx and enzalutamide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
    Location: University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan